Pharmaceutical giant Teva announces new CEO

Teva Pharmaceutical Industries, the world's largest maker of generic drugs, said Thursday it had appointed a new chief executive to replace Jeremy Levin, who left abruptly in October.

The new CEO of the Israeli-based company is Erez Vigodman, 54, who is currently a member of Teva's board of directors.

Teva said in a statement he will take up his new position on February 11.

Vigodman currently also worked as head of the agrochemical group Makhteshim Agan Industries. He has sat on the Teva board since 2009.

Levin spent less than two years on the job.

Media reports have said he left because of disagreements with the chairman of the Teva board and major shareholder Philip Frost over the terms of a cost-cutting restructuring plan.

In October Teva announced it would trim its global workforce of 46,000 jobs by 10 percent by the end of 2014.

Vigodman is Israeli and holds degrees from Tel Aviv University and Harvard Business School.

add to favorites email to friend print save as pdf

Related Stories

CEO of drug maker Teva out ahead job cuts (Update)

Oct 30, 2013

Israeli drug manufacturer Teva Pharmaceuticals Ltd. announced Wednesday its CEO had resigned, following a public uproar over a contentious restructuring plan set to cut thousands of jobs worldwide.

Israel's Teva to pay $718 million in Israeli taxes

Nov 11, 2013

Israel's Teva Pharmaceuticals Industries Ltd. says it has reached an agreement with the country's tax authority to pay roughly $718 million to settle a series of claims against the drug maker.

Pfizer, Teva reach deal to allow generic Viagra

Dec 17, 2013

Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.

Israeli generic drug giant Teva to buy Cephalon

May 02, 2011

Teva Pharmaceutical Industries, the world's largest generic drug maker, will buy US biopharma firm Cephalon in a $6.8 billion deal, the companies said in a joint statement Monday.

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

9 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments